Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Co. Ltd ADR (TAK)

Takeda Pharmaceutical Co. Ltd ADR (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...

TAK : 13.98 (-0.57%)
ARWR : 33.55 (-0.50%)
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...

TAK : 13.98 (-0.57%)
ARWR : 33.55 (-0.50%)
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

Takeda ( TSE:4502/NYSE:TAK ) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built...

TAK : 13.98 (-0.57%)
As Health Problems Mount Patients Welcome New Treatments

Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...

CRDL : 1.5687 (-3.46%)
CRDL.TO : 2.01 (-3.83%)
TAK : 13.98 (-0.57%)
ABT : 108.90 (-0.17%)
BMY : 79.65 (-0.41%)
NVO : 109.65 (-2.87%)
Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes

Improving your investing process tends to have high returns.

TAK : 13.98 (-0.57%)
GSK : 43.61 (-0.21%)
IIPR : 118.19 (+0.74%)
COST : 479.24 (-0.52%)
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial

Takeda ( TSE:4502/NYSE:TAK ) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks...

TAK : 13.98 (-0.57%)
Takeda Canada applauds Quebec's new Rare Disease Policy

/CNW/ - Takeda Canada Inc. ("Takeda Canada"), a values-based, R&D-driven biopharmaceutical leader, committed to discovering and delivering life-transforming...

TAK : 13.98 (-0.57%)
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58 th Annual Meeting of...

TAK : 13.98 (-0.57%)
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in...

TAK : 13.98 (-0.57%)
MRNA : 146.28 (+0.63%)
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022...

MRNA : 146.28 (+0.63%)
TAK : 13.98 (-0.57%)

Barchart Exclusives

Warby Parker (WRBY): Demographic Trends Point to a Bullish Case
While Warby Parker is one of the most disappointing public market debuts, at its current market value, it might be attractive as eye problems continue to rise. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar